Uniqure announces first quarter 2025 financial results and highlights of recent company progress

~ amt-130 granted breakthrough therapy designation by fda ~ ~ initial safety data from third cohort of phase i/ii study show amt-130 continues to be generally well-tolerated, with no treatment-related serious adverse events ~ ~ held type b fda meetings in the first and second quarters of 2025 to advance bla preparations for amt-130; regulatory update expected in the second quarter of 2025 ~ ~ amt-260 clinical data from first patient to be presented at epilepsy therapies & diagnostics development symposium on may 29, 2025 ~ ~ cash, cash equivalents and current investment securities of approximately $409.0 million as of march 31, 2025 expected to fund operations into second half of 2027 ~ ~ uniqure to host inaugural earnings call at 8:30 a.m. et ~ lexington, mass.
AMT Ratings Summary
AMT Quant Ranking